NO_LONGER_AVAILABLENot Applicable

Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine

Plain-language summary

The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of LEMS
✓. Over 18 years old
✓. Medically stable
✓. If female and premenopausal, have a negative urine pregnancy test prior to starting the 3,4 DAP, and, if premenopausal, be willing to practice an effective form of birth control such as "double-barrier contraception" during the study

Exclusion criteria

✕. Known sensitivity to 3,4 DAP
✕. History of past or current seizures
✕. History of severe asthma
✕. Believed by the investigator to be unable to comply with the protocol
✕. Unable to provide informed consent

Trial details

NCT IDNCT00994916

SponsorDavid Lacomis, MD

Sponsor typeOTHER

Study typeEXPANDED_ACCESS

View on ClinicalTrials.gov More Lambert-Eaton Myasthenic Syndrome trials